Changes in Hong Kong stocks | Pegasus Medical-B (09996) rose more than 6%, the chairman's holdings increased, demonstrating confidence that its TauriO subsidiary was recently approved for listing

The Zhitong Finance App learned that Peijia Medical-B (09996) rose by more than 6%, rising more than 22% during the month. As of press release, it rose 5.31% to HK$6.35, with a turnover of HK$10.97 million.

According to the news, on December 5, Peijia Healthcare announced that Chairman Dr. Zhang Yi plans to spend no more than HK$15 million to increase the company's shares in the open market. On December 11, Peijia Medical announced that its TauruRIO transcatheter aortic valve system was officially approved by the China Drug Administration, making it the first approved interventional treatment device for integrated positioning keys to aortic valve reflux (AR) through the meridian route.

CITIC Construction Investment previously released a research report stating that the company is in a leading position in the field of heart valve intervention in China. Since commercialization, TAVR products have had good clinical feedback, rapid product release, and market share has continued to increase; in addition, the company has a comprehensive and in-depth product development system in the field of aortic valve, mitral valve and tricuspid valve treatment, which continues to consolidate the company's leading position in the field of heart valves; the company expects three major products to be approved and commercialized domestically from the end of '25 to '26, helping the company's overall performance resume a rapid growth trend. The company's neurological intervention business is at the forefront of domestic companies. With the continuous enrichment of the product pipeline under development and the continuous promotion of commercialization of certified products, the company's neurological intervention business is expected to maintain a rapid development trend.